-
Mashup Score: 1Caring for Patients With Pulmonary Arterial Hypertension (PAH) During the COVID-19 Pandemic - 1 year(s) ago
Gustavo A. Heresi, MD, MS, Director of the Pulmonary Vascular and Chronic Thromboembolic Pulmonary Hypertension Program in the Department of Pulmonary and Critical Care Medicine in the Respiratory Institute at Cleveland Clinic discusses caring for patients with pulmonary arterial hypertension (PAH) during the COVID-19 pandemic. Pulmonary arterial hypertension is a rare, progressive disorder…
Source: CheckRareCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Gustavo A. Heresi, MD, MS, Director of the Pulmonary Vascular and Chronic Thromboembolic Pulmonary Hypertension Program in the Department of Pulmonary and Critical Care Medicine in the Respiratory Institute at Cleveland Clinic discusses the challenges of diagnosing and treating patients with pulmonary arterial hypertension (PAH). PAH is a rare, progressive disorder characterized by high […]
Source: CheckRareCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Gustavo A. Heresi, MD, MS, at Cleveland Clinic, discusses the challenges of diagnosing and treating patients with pulmonary arterial hypertension (PAH). @ClevelandClinic https://t.co/imNAz5a89D #raredisease #PAH #pulmonaryarterialhypertension
-
-
Mashup Score: 0Caring for Patients With Pulmonary Arterial Hypertension (PAH) During the COVID-19 Pandemic - 1 year(s) ago
Gustavo A. Heresi, MD, MS, Director of the Pulmonary Vascular and Chronic Thromboembolic Pulmonary Hypertension Program in the Department of Pulmonary and Critical Care Medicine in the Respiratory Institute at Cleveland Clinic discusses caring for patients with pulmonary arterial hypertension (PAH) during the COVID-19 pandemic. Pulmonary arterial hypertension is a rare, progressive disorder…
Source: CheckRareCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Gustavo A. Heresi, MD, MS, at Cleveland Clinic discusses caring for patients with pulmonary arterial hypertension (PAH) during the COVID-19 pandemic. @ClevelandClinic @BayerPharma @BayerUS https://t.co/6ncNHzTMWF #pulmonaryarterialhypertension #PAH #raredisease
-
-
Mashup Score: 1
Gustavo A. Heresi, MD, MS, Director of the Pulmonary Vascular and Chronic Thromboembolic Pulmonary Hypertension Program in the Department of Pulmonary and Critical Care Medicine in the Respiratory Institute at Cleveland Clinic discusses the challenges of diagnosing and treating patients with pulmonary arterial hypertension (PAH). PAH is a rare, progressive disorder characterized by high […]
Source: CheckRareCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Gustavo A. Heresi, MD, MS, at Cleveland Clinic, discusses the challenges of diagnosing and treating patients with pulmonary arterial hypertension (PAH). @ClevelandClinic https://t.co/imNAz5a89D #raredisease #PAH #pulmonaryarterialhypertension
-
-
Mashup Score: 2
Matters of the heart can sometimes be resolved from within. Pulmonary arterial hypertension, or PAH, caused by a thickening of the arterial walls and narrowing of the lumen can be fatal if left untreated. The use of vasodilators has been shown to improve the prognosis in only some cases.
Source: medicalxpress.comCategories: General Medicine News, Latest HeadlinesTweet-
Regulation is the name of the game in #pulmonaryarterialhypertension @CircAHA https://t.co/PAL57zl7DT
-
-
Mashup Score: 7Novel blood test helps evaluate severity in pulmonary arterial hypertension, a rare lung disease - 2 year(s) ago
Researchers at the National Institutes of Health have found that a novel blood test can be used to easily evaluate disease severity in patients with pulmonary arterial hypertension (PAH) and predict survivability. PAH is a rare, life-threatening condition that causes unexplained high blood pressure in the lungs. In early clinical studies, the researchers showed the test to significantly improve…
Source: medicalxpress.comCategories: General Medicine News, Latest HeadlinesTweet-
Novel #blood test helps evaluate severity in #pulmonaryarterialhypertension, a rare lung disease @nih_nhlbi @CircAHA https://t.co/Bjcx2M9bkt
-
-
Mashup Score: 0
The data obtained from the study supported the idea that IL-6 could be used as a potential marker for judging the efficacy of SSc.
Source: HCPLive®Categories: General Medicine News, Latest HeadlinesTweet-
New data from indicated that cytokine IL-6 in the serum of patients with #systemicsclerosis was associated with #interstitiallungdisease, #pulmonaryarterialhypertension (PAH), gastrointestinal involvement and cardiac involvement. https://t.co/UAgJ3sg9PS https://t.co/UAgJ3sg9PS
-
-
Mashup Score: 6Upfront riociguat and ambrisentan combination therapy for newly diagnosed pulmonary arterial hypertension: A prospective open-label trial - 2 year(s) ago
Initial combination therapy with an endothelin receptor antagonist (ERA) and riociguat in pulmonary arterial hypertension (PAH) has limited supporting data.
Categories: Cardiology News and Journals, Latest HeadlinesTweet-
#UPFRONT combination therapy with riociguat + ambrisentan improved PVR and risk in functional class III patients with #PulmonaryArterialHypertension, however there was a high rate of discontinuation (25%). https://t.co/tqwJlFGNzy From J. Weatherald et al. @AlbertaPHdoc https://t.co/frqtgzAe5N
-
-
Mashup Score: 2
Researchers in Japan identified 2 potential biomarkers for severity of pulmonary arterial hypertension (PAH) that can be measured without invasive procedures.
Source: AJMCCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
Study Identifies Potential Noninvasive Biomarkers for #PulmonaryArterialHypertension Severity: https://t.co/L4xhyHEuf1 https://t.co/O4LWDaMqCf
-
-
Mashup Score: 0Cost and Health Outcomes of Treprostinil and Selexipag Similar - 3 year(s) ago
Investigators propose oral treprostinil be considered when treating patients with pulmonary arterial hypertension.
Source: HCPLive®Categories: General Medicine News, Latest HeadlinesTweet-
More #CHEST2021 coverage! A new study presented this week considered the cost differences of oral treprostinil and selexipag, as well as the health outcomes associated with year-long treatment of patients with #pulmonaryarterialhypertension #PAH https://t.co/xXYctJ8lbK
-
Gustavo A. Heresi, MD, MS, at Cleveland Clinic discusses caring for patients with pulmonary arterial hypertension (PAH) during the COVID-19 pandemic. @ClevelandClinic @BayerPharma @BayerUS https://t.co/6ncNHzCby5 #pulmonaryarterialhypertension #PAH #raredisease